Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Find out how the Opto™ CLD workflow lets you generate the best production cell lines for complex antibody therapeutics with >99% monoclonality assurance in just days.
Dr. Shireen Khan presents a case study on how ChemPartner has leveraged the Beacon system to rapidly discover cross-reactive antibodies against the GPI-anchored uPA receptor.
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.